描述疾病发作:比较系统性红斑狼疮及其他风湿病患者与临床医生视角的混合方法研究
该混合方法研究结合国际共同制作的调查与深度访谈,比较系统性自身免疫风湿病(SARD)患者与临床医生对「发作」的视角。定量调查纳入443例SLE患者和258名临床医生,定性访谈纳入31例SARD患者和12名临床医生。结果显示双方在发作起始、识别及用药干预上存在显著差异,但在发作对健康状态的影响上有共识。
要点
- 患者与临床医生对17条发作相关陈述中的12条评分存在显著差异。
- 39%患者认为发作常在数分钟至数小时内开始,而临床医生仅14%(P<0.001)。
- 临床医生更倾向于认为发作需要增加(P=0.005)或启用新药(P<0.001)。
核心结论
- SARD患者与临床医生对发作的描述存在差异,主要涉及发作起始、识别和干预。
- 这些差异挑战了当前依赖临床医生来源的疾病活动度指标和生物标志物评估发作的做法。
- 研究强调需要整合患者与临床医生的视角。
研究设计与样本
- 混合方法研究,结合国际共同制作的调查与深度访谈。
- 定量调查纳入443例SLE患者和258名临床医生,对发作相关陈述进行Likert量表评分。
- 定性访谈纳入31例SARD患者和12名临床医生,进行主题分析。
- 定量与定性分析通过探索趋同、分歧和解释性发现进行三角验证。
主要发现
- 患者与临床医生对17条发作陈述中的12条平均评分存在显著差异。
- 关于发作起始,39%患者 versus 14%临床医生认为发作「经常」或「总是」在数分钟至数小时内开始(P<0.001)。
- 患者对「患者能判断」的评分显著高于临床医生(P<0.001),包括对前驱症状的感知。
- 临床医生显著更可能认为发作需要增加用药(P=0.005)或启用新药(P<0.001)。
- 双方对发作影响健康状态存在共识。
关键数值与推荐
- 定量调查中患者与临床医生对17条发作陈述进行Likert量表评分,12条存在显著差异。
- 发作起始在数分钟至数小时内「经常」或「总是」:患者39% vs 临床医生14%(P<0.001)。
- 患者对「患者能判断」评分显著高于临床医生(P<0.001)。
- 临床医生认为发作需要增加用药(P=0.005)或启用新药(P<0.001)的倾向显著更高。
临床怎么用
- 评估SLE及其他SARD发作时,应整合患者对发作起始、前驱症状和识别的描述。
- 不应仅依赖临床医生来源的疾病活动度指标和生物标志物来判断发作。
- 临床沟通中需关注患者对发作快速起始和自行识别能力的重视。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic autoimmune rheumatic diseases (SARDs) relapse and remit, with periods of increased disease activity called 'flares'. This study compared patient and clinician perspectives of flares. METHODS: Mixed-methods approach combining an international co-produced survey and in-depth interviews. SLE patients and clinicians rated statements about flares on Likert scales from 'never' to 'always'. Quantitative data were analysed using t tests and ANOVA. Patient and clinician interviews were analysed thematically. Quantitative and qualitative analyses were triangulated by exploring converging, diverging and explanatory findings across the datasets. RESULTS: Qualitative (N = 31 SARD patients, N = 12 clinicians) and quantitative (N = 443 SLE patients, N = 258 clinicians) results indicated differential patient and clinician perspectives. The main themes identified were: characteristics/consequences of flares; recognition of flares; and treatment for flares (medical and/or self-management). Patients and clinicians had significantly different mean ratings for 12/17 flare statements. Notably, regarding flare onset, 39% of patients compared with 14% of clinicians said flares 'often' or 'always' started within minutes or hours (P < 0.001). We found differences in identification of flares, with patients rating 'patient can tell' significantly higher than clinicians (P < .001), including awareness of prodromal symptoms. Clinicians were significantly more likely to think flares required increased (P = 0.005) or new (P < .001) medication. There was consensus about the impact of flares on wellbeing. CONCLUSION: We highlight differences in how SARD patients and clinicians describe flares, notably related to onset, recognition and intervention. These differences challenge the prevailing reliance on clinician-derived disease activity measures and biomarkers for flare assessment, highlighting the need for integration of patient and clinician perspectives.
引用
- Piper MA, Tunks A, Bourgeois JA, et al. Describing flares: a mixed methods study comparing patient and clinician perspectives in systemic lupus erythematosus and other rheumatic diseases. Rheumatology (Oxford). 2026. PMID: 42623093. doi:10.1093/rheumatology/keag443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。